Trials / Completed
CompletedNCT00080327
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 370 (planned)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | Tablets, Oral, 2mg, Once daily, 6 weeks. |
| DRUG | Aripiprazole | Tablets, Oral, 5mg, Once daily, 6 weeks. |
| DRUG | Aripiprazole | Tablets, Oral, 10mg, Once daily, 6 weeks. |
| DRUG | Placebo | Tablets, Oral, 0mg, Once daily, 6 weeks. |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2004-09-01
- Completion
- 2004-09-01
- First posted
- 2004-03-30
- Last updated
- 2013-11-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00080327. Inclusion in this directory is not an endorsement.